60 Degrees Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SXTP research report →
Price Chart
About the company
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis.
- CEO
- Geoffrey Stuart Dow
- IPO
- 2023
- Employees
- 3
- HQ
- Washington, DC, US
Get TickerSpark's AI analysis on SXTP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.10M
- P/E
- -0.11
- PEG
- -0.00
- P/S
- 2.40
- P/B
- 2.04
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- 24.08%
- Op Margin
- -971.89%
- Net Margin
- -921.33%
- ROE
- -284.39%
- ROIC
- -913.44%
Latest fiscal year · YoY change
- Revenue
- $1.01M+65.5%
- Gross Profit
- $223.78K+0.4%
- Op Income
- $-7,758,579
- Net Income
- $-7,368,325+7.3%
- EPS
- $-11.73+84.2%
- OCF Growth
- -21.3%
- FCF Growth
- -21.2%
- 52W High
- $8.62
- 52W Low
- $0.46
- 50D MA
- $0.90
- 200D MA
- $1.53
- Beta
- 2.47
- RSI (14)
- 30
- Avg Volume
- 407.29K
No earnings-call transcripts are available for SXTP yet.
- Free Float
- 69.5%
- Shares Outstanding
- 4.48M
- Float Shares
- 3.12M
of shares held by institutions
8 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 14.55K | 0 |
| Citadel Advisors LLC | 14.29K | ▼ 8.07K |
| Ubs Group AG | 13.53K | ▼ 66 |
| Barclays PLC | 1.48K | ▲ 423 |
| Robinhood Markets, Inc. | 84 | ▲ 84 |
| Tower Research Capital LLC (Trc) | 64 | ▲ 64 |
| Osaic Holdings, Inc. | 25 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Knight Therapeutics Inc. | other | 0 |
| Jun 12, 26 | DOW GEOFFREY S | buy | 7,350 |
| May 13, 26 | Francois Eric | other | 0 |
| Dec 15, 25 | DOW GEOFFREY S | buy | 9,670 |
| Dec 11, 25 | DOW GEOFFREY S | buy | 3,613 |
| Dec 10, 25 | DOW GEOFFREY S | buy | 9,350 |
| Sep 12, 25 | DOW GEOFFREY S | other | 7,201 |
| Sep 26, 24 | Landon Kristen | other | 4,167 |
| Jan 17, 25 | Landon Kristen | other | 4,540 |
| Feb 12, 24 | Landon Kristen | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SXTP coverage
Recent articles, reports, and earnings notes.
No research on SXTP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SXTP report →Critical Survey: GSK (NYSE:GSK) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
defenseworld.net · Nov 14
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
globenewswire.com · Oct 28
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
globenewswire.com · Oct 27
Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
defenseworld.net · Oct 17
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
globenewswire.com · Oct 6
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
globenewswire.com · Oct 1
Reviewing Innoviva (NASDAQ:INVA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
defenseworld.net · Sep 16
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.